AUM Biosciences attended the 24th Annual International Partnering Conference, Bio-Europe, held in Copenhagen, Denmark on November 5-7, 2018.

Denmark, 5 - 7 November 2018

AUM Biosciences attended the 24th Annual International Partnering Conference, Bio-Europe, held in Copenhagen, Denmark on November 5-7, 2018. This year’s theme was “Initiate New Partnerships Though Life Science Partnering”.

The event is Europe’s largest life science partnering conference offering world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings making this event an unrivalled forum for companies across the biotech value chain to meet and do business.

More information about the event can be found here.

We enjoyed meeting with potential partners.

For any additional queries, please contact pr@aumbiosciences.com

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit www.aumbiosciences.com